세계의 IV(정맥내) 투여 이부프로펜 시장 보고서 : 제품 용량, 적응증, 연령층, 지역별(2024-2032년)

The global intravenous (IV) ibuprofen market size reached US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.79% during 2024-2032.

Ibuprofen belongs to the nonsteroidal anti-inflammatory drug (NSAID) class used to treat inflammation, pain, and fever. It inhibits cyclooxygenase COZ-1 and COX-2 enzymes that are required for the synthesis of prostaglandins (PG). Intravenous (IV) ibuprofen is used alone or with other medicines to relieve mild to severe discomfort. It is injected directly into the vein to block the body's production of certain natural substances that cause inflammation. It helps to reduce narcotic analgesic requirements and lower pain levels with an excellent safety profile. IV ibuprofen also aids in improving pain control and reducing the usage of opioid drugs in orthopedic and abdominal surgeries and fever.

Intravenous (IV) Ibuprofen Market Trends:

The steadily rising geriatric population and the increasing prevalence of arthritis, cardiovascular diseases (CVDs), and cancer across the globe are creating a positive outlook for the market. In line with this, the widespread product adoption to manage and treat inflammatory diseases, rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, and osteoarthritis is favoring the market growth. Moreover, hectic working schedules and unhealthy lifestyles, along with a consequent decline in physical activity and proper nutrition, have led to a rise in the incidences of chronic diseases, which is acting as another growth-inducing factor. Apart from this, the increasing product utilization to treat mild fever, dental pain, gastrointestinal pain, and ductus arteriosus in pediatrics is providing an impetus to the market growth. Moreover, IV ibuprofen is employed to relieve muscle or rheumatic pain, backache, neuralgia, sprains, strains, sports injuries, and musculoskeletal diseases, which is facilitating the market growth. Furthermore, the increasing demand for IV ibuprofen in orthopedic patients post knee or hip replacement surgeries to reduce pain and morphine use is positively influencing the market growth. Other factors, including significant improvements in the healthcare infrastructure, growing health consciousness among individuals, and the rising expenditure capacities of consumers, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global intravenous (IV) ibuprofen market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product dose, indication and age group.

Breakup by Product Dose:

100 Mg Dose

200 Mg Dose

400 Mg Dose

800 Mg Dose

Breakup by Indication:

Pain/Inflammatory

Fever

Breakup by Age Group:

Pediatrics

Adults

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.

Key Questions Answered in This Report

• 1. What was the size of the global Intravenous (IV) ibuprofen market in 2023?
• 2. What is the expected growth rate of the global Intravenous (IV) ibuprofen market during 2024-2032?
• 3. What are the key factors driving the global Intravenous (IV) ibuprofen market?
• 4. What has been the impact of COVID-19 on the global Intravenous (IV) ibuprofen market?
• 5. What is the breakup of the global Intravenous (IV) ibuprofen market based on the indication?
• 6. What is the breakup of the global Intravenous (IV) ibuprofen market based on the age group?
• 7. What are the key regions in the global Intravenous (IV) ibuprofen market?
• 8. Who are the key players/companies in the global Intravenous (IV) ibuprofen market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Intravenous (IV) Ibuprofen Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Dose

• 6.1 100 Mg Dose
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 200 Mg Dose
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 400 Mg Dose
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 800 Mg Dose
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Indication

• 7.1 Pain/Inflammatory
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Fever
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Age Group

• 8.1 Pediatrics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Adults
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Cumberland Pharmaceuticals Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Hyloris Pharmaceuticals SA
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
  • 14.3.3 Recordati Rare Diseases Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 VALMOR Laboratories CA
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Xgen Pharmaceuticals Djb Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio